Moleculin Biotech Inc
MBRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.13M
Close$
$7.19
1262.3% upside
Current Fair Value
1262.3% upsideUndervalued by 1262.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.13 Million |
|---|---|
| Enterprise Value | $-2,989,468.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-28.42 |
| Beta | 1.92 |
| Outstanding Shares | 5,680,717 |
Return
| Return on Equity | -261.73% |
|---|---|
| Return on Assets | -143.82% |
| Return on Invested Capital | -63.41% |
Valuation & Multiples
| P/E Ratio | -0.05 |
|---|---|
| PEG | 68.96 |
| Price to Sales | - |
| Price to Book Ratio | 0.26 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.4 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.05 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
$-1.46
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.44
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.27%▼ 0.42% |
|---|---|
| Total Invested | $518,510▲ 49.04% |
| Investors Holding | 18▼ 2.00% |
ESG Score
No data
About Moleculin Biotech Inc
13 employeesMoleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses. The Company's clinical stage drugs a...